HISUN(SH:600267) Ge Long Hui·2025-12-23 09:19Core Viewpoint - The company has received approval from the National Medical Products Administration for a supplemental application for Everolimus tablets, adding a new 2.5mg specification to the already approved 5mg version [1] Group 1: Product Approval - The new 2.5mg specification of Everolimus is intended for adult patients with advanced renal cell carcinoma who have failed previous treatments with Sunitinib or Sorafenib [1] - Everolimus is also indicated for various other conditions, including advanced pancreatic neuroendocrine tumors and tuberous sclerosis complex-related tumors [1] - The original manufacturer of Everolimus is Novartis, and the product has been approved under the new category 4, which is considered equivalent to passing the consistency evaluation [1] Group 2: Market Statistics - The global sales of Everolimus tablets are projected to be approximately $1.013 billion in 2024, with domestic sales around $11.7842 million [2] - For the first half of 2025, global sales are estimated at about $497 million, with domestic sales expected to be around $5.4255 million [2] - The company has invested approximately 7.4042 million RMB in the research and development of the 2.5mg specification of Everolimus [2]